Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients

Figure 5

Comparison of the expression of immunotherapy response biomarkers in the high- and low-risk groups. (a) Comparisons of Tumor Immune Dysfunction and Exclusion (TIDE) Score, interferon-gamma (IFNG), microsatellite instability (MSI) Score, Merck18, CD274, CD8, CTL.flag (an indicator of the expression of five cytotoxic T-lymphocyte markers), Dysfunction (T cell dysfunction), Exclusion (T cell exclusion), myeloid-derived suppressor cells (MDSC), cancer-associated fibroblasts (CAF), and tumor-associated macrophages (TAM) M2 in the high- and low-risk groups. (b) Comparisons of mRNA expression of immune checkpoint molecules (PD-L1, PD-1, CTLA3, TIM-3, LAG-3, and TIGIT) in the high- and low-risk groups.

(a)

(b)

(c)

(d)

(e)